据了解，迪瑞医疗国际市场经过二十余年的积累，已成功实现从早期的"多点布局"到如今的"精耕细 作"战略升级。公司基于全球医疗器械行业发展趋势及区域市场需求特点，动态调整国际市场策略，以 十二个重点国家市场为核心，集中优势资源打造核心市场竞争力。在人才队伍建设方面，销售团队在继 续落实本地化的基础上，成立多部门组成的项目组推动仪器、试剂本地化许可生产业务，加强国际公共 关系管理，利用仪器和试剂多元化优势，提高重点国际市场基础医疗领域的市场占有率。 公开资料显示，迪瑞医疗的七大系列产品远销120多个国家和地区，主推的尿分、生化、血球等仪器和 试剂产品已拥有稳定的销售渠道和品牌影响力。(燕云) 8月25日晚间，迪瑞医疗（300396）发布2025年半年度报告，报告显示，上半年公司营业收入3.51亿 元，较上年同比下降60.07%，归属于上市公司股东的净利润亏2831万元，较上年同比下降117.13%。其 中，国际市场保持相对平稳，国际市场营业收入比上年同期增两成。 迪瑞医疗表示，公司持续推动国内、国际双轮驱动战略。近年持续强化本地化管理，产品升级迭代注 册。报告期内，取得了阶段性成果，多款高速机型完成部分国家的注册， ...

Financial Performance - The company achieved total revenue of 1.742 billion yuan in 2024, a decrease of 7.61% year-on-year, primarily due to a decline in agency product and testing service income [3] - Self-produced products generated revenue of 837 million yuan, remaining stable compared to the previous year [3] - Net profit attributable to shareholders was 258 million yuan, a year-on-year increase of 0.56% [3] - Net profit attributable to shareholders after deducting non-recurring gains and losses was 220 million yuan, an increase of 12.67% year-on-year [3] Strategic Focus - The company will continue to implement a strategy centered on in vitro diagnostic instruments and products, aiming for collaborative development between diagnostic products and services [3] - Plans to enhance product variety and quality through continuous technological innovation and product research and development [3] Market Challenges - The in vitro diagnostic industry is facing pressure due to national medical insurance cost control and centralized procurement, impacting short-term performance [9][19] - The company aims to strengthen refined management, implement large-scale production, and optimize the supply chain to improve operational efficiency and market share [10][19] International Expansion - In 2024, the company participated in major overseas exhibitions, expanding its business to six new countries and regions [12] - Plans to accelerate product international market registration and certification, establishing an "International Trade Center" in Shenzhen to enhance international sales capabilities [13] Technological Development - The company is focusing on automation, precision medicine, and personalized diagnostics as key trends in the in vitro diagnostic industry [11][15] - Ongoing investment in R&D to enhance product performance and develop new products in the fields of biochemistry, mass spectrometry, and precision lipid testing [15][16] Future Outlook - The company anticipates that the aging population and increasing life expectancy in China will continue to drive growth in the in vitro diagnostic industry [11] - The company is committed to adapting to industry changes and enhancing its competitive position through strategic adjustments and technological advancements [19]